Trials / Withdrawn
WithdrawnNCT01452334
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the side effects of treatment with the monoclonal antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the dose that should be recommended for use in future studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-936559 (Anti PD-L1) | Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2011-10-14
- Last updated
- 2012-02-23
Source: ClinicalTrials.gov record NCT01452334. Inclusion in this directory is not an endorsement.